BioCrossroads Announces the 2024 Indiana Life Sciences Summit, “Transforming Healthcare: Indiana’s Role in Revolutionizing Diabetes and Obesity Management”

INDIANAPOLIS (July 15, 2024) – BioCrossroads is excited to announce the annual Indiana Life Sciences Summit, scheduled for November 7, 2024, at the Biltwell Event Center in Indianapolis. The Summit will focus on “Transforming Healthcare: Indiana’s Role in Revolutionizing Diabetes and Obesity Management,” highlighting Indiana’s significant impact on healthcare, particularly in the development of GLP-1 therapies, which are revolutionizing diabetes and obesity care, and the opportunities that lie ahead for continued advancement of future therapies. GLP-1 therapies, developed and delivered through the relentless efforts of Indiana’s researchers and companies, have emerged as vital tools in managing obesity and diabetes, offering new hope to millions worldwide.

Nationwide, more than 38 million[1] Americans are living with diabetes, with obesity being linked to as many as 53 percent of new cases of type 2 diabetes each year.[2] In Indiana, more than 12% of the adult population is living with diabetes, with an estimated 31,200 more adults expected to be diagnosed every year,[3] and Indiana’s obesity rate is higher than the national average and has been increasing steadily over the past 20 years. As of 2021, 36.3 percent, more than two-thirds of adults in Indiana were obese and 33.3% were overweight. This places Indiana 12th in the nation for obesity[4]—making the demand for effective solutions even more critical.

“Indiana’s contributions to GLP-1 therapies are also setting new standards in the global fight against obesity and metabolic diseases,” said Vince Wong, CEO of BioCrossroads. “The 2024 Indiana Life Sciences Summit is a compelling platform to highlight the pivotal role Indiana has played in bringing transformative innovation to address some of the most challenging unmet needs in healthcare and to gain insights into future developments that will benefit patients, not only in Indiana, but throughout the world. By bringing together industry leaders, researchers, and patients, we aim to foster collaboration and inspire further breakthroughs in diabetes and obesity care.”

A highlight of the event will be the presentation of the prestigious August M. Watanabe Life Sciences Champion of the Year Award, honoring exceptional contributions to life sciences in Indiana. Named in memory of Dr. August “Gus” Watanabe, a visionary in the industry, this award recognizes outstanding achievements and significant contributions in life sciences.

Secure your front row seat for this impactful discussion. Register now and join BioCrossroads at the 2024 Indiana Life Sciences Summit. For more information and to register, please visit BioCrossroads.

Transforming Healthcare, Indiana’s Role in Revolutionizing Diabetes and Obesity Management

Save the Date: November 7, 2024
Location: Biltwell Event Center, Indianapolis
Time: 9:00 AM – 3:30 PM

Register Here

 

About BioCrossroads
Established as a catalyst to advance, grow, and invest in Indiana’s life sciences sector, BioCrossroads is an initiative of the Central Indiana Corporate Partnership (CICP). It supports the region’s existing enterprises and encourages new business development. The initiative fosters public-private collaboration by uniting a diverse range of academic, industry, and philanthropic stakeholders, all collectively focused on advancing Indiana’s life sciences sector. Committed to supporting the growth of capital investments and talent development, BioCrossroads provides support to both existing and new life sciences enterprises, including the Indiana Health Information Exchange, OrthoWorx, and the Indiana Biosciences Research Institute. BioCrossroads champions the advancement of cutting-edge research and development, plays a crucial role in building and nurturing a robust talent pipeline, and is dedicated to establishing Indiana as a thriving hub for life sciences manufacturing. To learn more about BioCrossroads, visit crossroadshealthventures.com.

[1] CDC National Diabetes Statistics Report [2] American Heart Association Obesity and Diabetes Link [3] American Diabetes Association. The Burden of Diabetes in Indiana [4] Richard M. Fairbanks Foundation, Indiana’s Obesity Epidemic

In a pivotal moment for Indiana’s life sciences sector, Vince will play a crucial role in championing the newly released life sciences industry strategy.

INDIANAPOLIS, [January 31, 2024] — Following a thorough national search, BioCrossroads, a catalyst for Indiana’s life sciences sector, today announced the appointment of Vince Wong as its new president and CEO. An esteemed leader with a rich background in healthcare and life sciences, Vince takes the helm at BioCrossroads ready to harness his vast expertise to elevate the organization’s impact on Indiana’s life sciences ecosystem.

Vince’s extensive experience at both multinational and venture backed start-up life science companies, coupled with deep-rooted insights into the life sciences sector, both locally and nationally, position him as a visionary leader who will help drive the recently released life sciences strategy for Indiana. Read the report: TEConomy Partners: A Strategic Roadmap for Advancing Indiana’s Life Sciences Industries

Vince most recently served as chief commercial officer at Geneoscopy, a venture-backed company focused on developing RNA-based gastrointestinal diagnostics. At Geneoscopy, Vince oversaw business development, governmental affairs, market access, marketing, sales, and communications, and helped secure over $100M in venture financing. Prior to that role, he had an impressive 18-year tenure at Roche Diagnostics, serving in senior leadership roles—most recently as vice president of sales, point of care diagnostics. Vince also serves as Executive in Residence at IU Ventures and a board director of both public and private life science companies.

“The life sciences sector is a vital, growing cornerstone of Indiana’s economy and the opportunity to lead BioCrossroads is an incredible honor,” Vince said. “I am eager to collaborate with our team, our partners, and the wider life sciences community to enhance our ability to develop and manufacture innovative treatments and interventions for people not just in Indiana, but on a global scale.”

A proud native Hoosier, Vince has been an active community leader, having served on numerous boards of directors, including the International Violin Competition of Indianapolis, Dance Kaleidoscope, Asian American Alliance, Inc., the Indianapolis Chamber of Commerce, and the Indianapolis Museum of Art. Vince was one of the Indianapolis Business Journal’s 2001 Forty Under 40 honorees.

Vince earned his BA from the University of Notre Dame, his law degree from Indiana University School of Law, Bloomington, and MBA from Northwestern University’s Kellogg School of Management.

“Vince embodies the leadership qualities and extensive life sciences experience that are quintessential for the role of CEO at BioCrossroads,” said Dan Peterson, chair of the BioCrossroads Board of Directors. “His commitment to leveraging innovation for the greater good aligns seamlessly with our objectives and strategy and we are enthusiastic about his ability to lead our life sciences sector.”

Indiana is home to more than 2,700 life sciences firms that employ 64,000 workers. The sector produces $77 billion annually in economic impact, and Indiana ranks third in the U.S. in life sciences exports with $13 billion in 2022 alone. As Vince steps into his new role, he is poised to leverage Indiana’s robust life sciences ecosystem to help guide the industry’s strategic vision.

“Building upon the state’s life sciences landscape, BioCrossroads remains committed to supporting the sector’s continued growth and innovation, resulting in products, businesses, and collaborations that directly enhance the quality of health and well-being across Indiana,” said Melina Kennedy, CEO, Central Indiana Corporate Partnership. “With Vince’s leadership, BioCrossroads will extend its track record of fostering a vibrant ecosystem centered on groundbreaking research and development, enhanced manufacturing capabilities, and expanded workforce opportunities.”

BioCrossroads’ work will be especially focused in areas where Indiana possesses unique strengths, like metabolic disorders, diabetes, radiopharmaceuticals, orthopedics, oncology, and neurodegenerative diseases, including Alzheimer’s.

“We’re poised to strengthen Indiana’s position in the life sciences sector significantly,” Vince said. “By bolstering our state’s innovation assets, supply chain, reshoring manufacturing capabilities, and leveraging our competitive environment and incentives, we aim to attract and retain top talent. It’s about creating a cohesive ecosystem where innovation, research, and community well-being are interlinked and mutually reinforcing.”

Vince officially joined BioCrossroads today, January 31, becoming the fourth leader in the organization’s history.

###

About BioCrossroads

Established as a catalyst to advance, grow and invest in Indiana’s life sciences sector, BioCrossroads is an initiative of the Central Indiana Corporate Partnership (CICP). It supports the region’s existing enterprises and encourages new business development. The initiative fosters public-private collaboration by uniting a diverse range of academic, industry, and philanthropic stakeholders, all collectively focused on advancing Indiana’s life sciences sector. Committed to supporting the growth of capital investments and talent development, BioCrossroads provides support to both existing and new life sciences enterprises, including the Indiana Health Information Exchange, OrthoWorx, and the Indiana Biosciences Research Institute. BioCrossroads champions the advancement of cutting-edge research and development, plays a crucial role in building and nurturing a robust talent pipeline, and is dedicated to establishing Indiana as a thriving hub for life sciences manufacturing. To learn more about BioCrossroads, visit https://crossroadshealthventures.com/.

Vince Wong Biography

Vince Wong brings significant valuable multi-national and start-up company experience to BioCrossroads. Vince, who became CEO on January 31, 2024, most recently was chief commercial officer at Geneoscopy, a venture-backed start-up company focused on developing gastrointestinal diagnostics. His responsibilities included business development, government affairs, market access, sales, marketing, and communications. He also helped raise over $100M in venture capital. Vince serves as a director on the board of Bionano Genomics (Nasdaq: BNGO) and Executive in Residence with IU Ventures. Prior to Geneoscopy, Vince enjoyed an 18-year career at Roche Diagnostics, where he held senior leadership roles in several functions across various disease areas. A native Hoosier, Vince has deep Indiana roots and served on the boards of numerous civic and arts organizations, including the International Violin Competition of Indianapolis, Dance Kaleidoscope, the Indy Chamber, Asian American Alliance, and the Indianapolis Museum of Art and was recognized as 40 Under Forty by the Indianapolis Business Journal. He earned a BA in economics and government from the University of Notre Dame, a JD from Indiana University’s Maurer School of Law, and an MBA from Northwestern University’s Kellogg School of Management. Vince Wong on LinkedIn

 

Jane Dunigan-Smith, Senior Vice President and Chief Strategy Officer, BioCrossroads

In today’s rapidly advancing world, Indiana stands at the forefront of innovation and economic development in the life sciences sector.

Contributing $77 billion in economic impact statewide and employing 64,000 Hoosiers who have made incredible achievements, the sector’s performance is a testament to the collaborative efforts that have established Indiana as a global leader in life sciences. The state now leads the nation in pharmaceutical exports and ranks third nationally in overall life sciences exports, totaling $13 billion in 2022 alone.

As technology continues to revolutionize the industry, we have taken significant steps to reassess Indiana’s life sciences sector strategies. This involves understanding the needs of our research institutions, industry enterprises, and other stakeholders. Our responsibility is to adapt and align our focus to meet these evolving demands, through four key areas:

Understanding Growth Dynamics:

Indiana is not just participating in the global life sciences landscape; we are setting the pace. Our sector, substantial and well-established, is evolving into a powerhouse that defines industry standards and shapes the future of global healthcare and biotechnology. It’s our continuous pursuit of excellence and innovation that propels us beyond traditional growth, transforming every challenge into a strategic opportunity to showcase our leadership. Our focus is to continue cultivating a thriving ecosystem by enhancing our solid sector foundations and embracing forward-thinking strategies that place us at the forefront of a dynamic and ever-expanding industry.

Commitment to Continuous Growth:

Our goal is not just to sustain but to accelerate growth. The life sciences sector has shown remarkable resilience and adaptability, demonstrated by a 14% increase in job growth from 2018 to 2022. We aim to build upon this momentum, ensuring that our life sciences industries remain vital contributors to Indiana’s economic health.

Connecting the Dots:

Our assessment indicates that Indiana has all the necessary components for success. The focus on workforce development, highlighted in the Governor’s 2024 agenda, aims to create a skilled workforce vital for attracting new operations and improving our capabilities, benefiting our communities. By improving training and fostering education-industry partnerships, we can help cultivate careers to advance the sector.

The Road Ahead:

Embracing the changes brought about by evolving workforce demands and advancing technology, this strategy acts as a roadmap, guiding us toward achieving our ambitious goals. We believe in the power of collaboration and are committed to leveraging our strong partnerships and innovative tools to make these goals a reality.

Indiana’s life sciences sector is key to our economic success. The pharmaceutical industry, a leader in research, development, manufacturing, and distribution, boosts our economy and provides quality job opportunities. Currently second in U.S. pharmaceutical manufacturing as measured by GDP contribution per capita, Indiana aims to become number one, backed by our capabilities, innovative tools, and skilled workforce.

The medical devices sector, adding $3.8 billion, drives innovation and job creation, supporting startups and established companies. By establishing strategic manufacturing hubs, we aim to strengthen domestic manufacturing and create even more quality jobs.

As senior vice president and chief strategy officer at BioCrossroads, I’ve seen the significant impact of these industries on Indiana’s economy and health landscape. Indiana’s life sciences sector reflects our state’s innovation and resilience, and we can continue to lead in this vital field. This strategy was developed in partnership with a diverse range of industry stakeholders, and a continued, unified effort will be key to shaping a future where life sciences remain central to our state’s economic and social wellbeing.

Read the full report from TEConomy Partners: A Strategic Roadmap for Advancing Indiana’s Life Sciences

INDIANAPOLIS (Nov. 9, 2023) — The BioCrossroads Board of Directors today named Bruce T. Lamb, PhD, as the recipient of the 2023 August M. Watanabe Life Sciences Champion of the Year Award. Lamb is the executive director of the Stark Neurosciences Research Institute at Indiana University School of Medicine and co-director of the Neurosciences Institute, a partnership between Indiana University Health and IU School of Medicine.

The prestigious honor, named in tribute to BioCrossroads’ late Chairman August Watanabe, was given to Lamb at today’s Indiana Life Sciences Summit in recognition of his globally significant research into the causes of and potential treatments for Alzheimer’s disease as well as his many years of advocacy to increase research funding and raise awareness for challenges the disease brings to families and caregivers.

“As we were planning our 2023 Life Sciences Summit, which focuses on Indiana’s globally significant work related to Alzheimer’s disease, one name kept coming up as the catalyst or force behind much of the progress being made: Dr. Bruce Lamb,” said Dan Peterson, chair of the BioCrossroads Board of Directors. “It was clear who had earned our annual Watanabe award.”

More than 6 million Americans 65 and older have Alzheimer’s disease, and the number of Hoosiers with Alzheimer’s is expected to increase 18 percent between 2020 and 2025. Several Indiana researchers and thought leaders are on the forefront of the battle to find a cure for people living with Alzheimer’s, as well as to support those who care for them. The Summit brought dozens of leaders, including Lamb, together to discuss how work being done in Indiana is contributing significantly to progress in both areas.

Lamb, an IU Distinguished Professor, oversees Stark Neurosciences Research Institute, a collaborative team of more than 100 faculty investigators from IU with a collective $75 million in funding from the National Institutes of Health (NIH) in nine research interest groups—addiction, neurodegenerative disorders, neurodevelopment, advanced imaging, ocular neurobiology, pain, psychiatric disorders, spinal cord and brain injury, and stem cell research. In 2010, when funding for Alzheimer’s research was challenging, he and the Alzheimer’s Association recruited 60 Alzheimer’s researchers from across the country to participate in a relay-style bicycle ride spanning 4,500 miles from San Francisco to Capitol Hill. Along the way, they collected 110,000 signatures from Americans who wanted to see more research funding for Alzheimer’s disease. Since that time, federal funding for Alzheimer’s research has increased more than 700 percent.

Among Lamb’s achievements:

Lamb began his professional career at Case Western Reserve University and also served at the Cleveland Clinic. He joined IU School of Medicine as executive director of the Stark Neurosciences Research Institute in 2016. His laboratory works on basic and translational science of Alzheimer’s disease, with a focus on animal models of Alzheimer’s disease, discovery of new therapeutic targets, the role of immune pathways in the development and progression of Alzheimer’s disease, and the role of traumatic brain injury as an environmental modifier for the development of Alzheimer’s pathologies. In 2020, Lamb became co-director of the IU School of Medicine-IU Health Neuroscience Institute, which combines clinical care, research and education across all areas of neuroscience.

Lamb is actively involved in advocacy for increased research funding for the disease and has received multiple honors including the National Civic Award and the Zaven Khachaturian Lifetime Achievement Award from the Alzheimer’s Association. He is also a Fellow of the American Association for the Advancement of Science. He serves on the Alzheimer’s Association Board of Directors and chairs the organization’s Medical and Scientific Advisory Group, while also serving on the Indiana chapter board.

Lamb received his bachelor’s degree from Swarthmore College and his PhD from the University of Pennsylvania prior to a post-doctoral fellowship at Johns Hopkins University.

Read about previous August M. Watanabe Life Sciences Champion of the Year award winners here.

 

About BioCrossroads: BioCrossroads, is the Central Indiana Corporate Partnership’s (CICP) initiative to grow, advance and invest in the life sciences. It is a public-private collaboration that supports the region’s existing research and corporate strengths while encouraging new business development. BioCrossroads invests capital and provides support to life sciences businesses, launches new life sciences enterprises (including the Indiana Health Information Exchange, OrthoWorx and the Indiana Biosciences Research Institute,) expands collaboration and partnerships among Indiana’s life science institutions, promotes science education and markets Indiana’s life sciences industry.

INDIANAPOLIS (May 9, 2023) – BioCrossroads today released the seventh edition of its Book of Data and Organizations and announced that the resource used to foster collaboration and networking among Indiana’s growing network of healthcare and life sciences companies, organizations and professionals, will now be available only in digital form on the organizations’ website under the Resources/Network tab.

“This resource has quintupled in size since we first created it in 2020 and is used to help health data professionals and others become more aware of the data, talent, and technology resources available, and build solutions where there are gaps,” said Darshan Shah, senior vice president and chief data officer for BioCrossroads. “Now, as a wiki, it will be an even better resource to help drive collaboration across the sector.”

Indiana’s life sciences sector contributed $77 billion to the state’s economic output last year and exported $13 billion in related goods. More than 63,000 Hoosiers currently work within the more than 2,700 companies operating in the sector. Many of those enterprises, and the state’s three research universities, contribute greatly to innovations in the field.

Shah worked with Indiana University Masters in Data Science students to convert the hard copy version of the book into digital form. Prior to the Book of Data, there was no single resource cataloging all the disparate health data assets throughout the state. Growth in the sector means the book must be updated often to keep pace.

With the digital offering, organizations can add themselves to the resource and edit their sections to reflect real-time changes. BioCrossroads will maintain control of the site and organizations would only receive access to update their pages to maintain accuracy.

The book includes snapshot information on more than 50 enterprises representing Indiana’s industry, government, health systems, academia, and digital health startups, as well as four cross-organizational initiatives to demonstrate where collaboration is driving impact.

“These organizations have tremendous data and technology resources that are driving transformative healthcare and life sciences work locally and globally,” Shah said. “Connecting all those who are doing this important work can help speed access and collaboration and help move Indiana’s health innovation farther, faster.”

About BioCrossroads: BioCrossroads is Indiana’s initiative to grow, advance and invest in the life sciences. It is a public-private collaboration that supports the region’s existing research and corporate strengths while encouraging new business development. BioCrossroads invests capital and provides support to life sciences businesses, launches new life sciences enterprises (including the Indiana Health Information Exchange, OrthoWorx and the Indiana Biosciences Research Institute,) expands collaboration and partnerships among Indiana’s life science institutions, promotes science education and markets Indiana’s life sciences industry.

INDIANAPOLIS (April 27, 2023) – BioCrossroads, Indiana’s initiative to grow the state’s life sciences sector, today announced seven new members to its board of directors.

“We are delighted to welcome these leaders and innovators to our board and look forward to benefiting from their vast experience, skills and intellect,” said Dan Peterson, board chair for BioCrossroads. “Indiana’s life sciences sector has experienced tremendous growth over the past 20 years, and the board will continue to be instrumental as we continue to fuel momentum for this globally significant sector.”

Kennedy and Botteron join as CICP representatives, with Botteron serving on the executive committee.

Hasler served as president of Purdue Research Foundation where he was responsible for protecting the University’s intellectual property and managing its entrepreneurial and technology transfer activities and helping move Purdue’s life-changing innovations through commercialization to the benefit of the public. He also served as Indiana’s Secretary of Commerce, attracting a record-breaking 254 companies to the State of Indiana in fiscal year 2012 and had an extensive, 31-year career at Eli Lilly and Company.

Langham holds and has held significant leadership roles in both state and industry organizations including pharmaceutical/life sciences, food and beverage, automotive, retail, and other sectors with complex supply chains. Langham opened trucking and air freight franchises three years out of college, then sold them and co-founded Langham Logistics, Inc. in 1987.

Schnell is an internationally renowned theoretical and mathematical biologist. He has published more than 150 peer-reviewed publications, one book and has received multiple awards in recognition of his research and teaching endeavors. His work has substantially altered the view of measuring and modeling enzyme-catalyzed reactions under non-physiological and physiological conditions. He has also made substantive contributions in diverse areas by developing mathematical models of complex physiological systems.

Shrivastav’s research on voice acoustics, speech perception and production help develop tools for disease detection and diagnostics, tracking treatment outcomes and improving hearing aid, cochlear implants, and other hearing devices. He is a Fellow of the National Academy of Inventors and the American Speech, Language and Hearing Association. From 2015 until 2021, he served as Vice President for Instruction at the University of Georgia, where he oversaw enrollment management, student success, and overall infrastructure for teaching and learning.

Yount has more than 25 years of drug development experience across pharma, CRO and technology sectors. She has been at Labcorp Drug Development since August 2021 and is accountable for enterprise client solutions and business strategy. Previously, she held senior leadership roles at Medidata Solutions that included product development, customer success, corporate integration and strategic consulting. She spent 10 years at Eli Lilly and Company in data management, clinical operations, clinical pharmacology and statistics.

Peterson thanked departing board members: Claire Fiddian-Green, David L. Johnson, Patty Martin, Theresa Mayer and JJ Spegele.

“BioCrossroads has benefitted greatly from each of the community and life sciences leaders who have helped guide us,” Peterson said. “Their impact will be felt for generations.”

In addition to the new members and Peterson, the BioCrossroads board is also comprised of the following individuals. Asterisk denotes executive committee membership:

-30-

About BioCrossroads

BioCrossroads (www.crossroadshealthventures.com) is Indiana’s initiative to grow the life sciences region’s research, a public-private collaboration that supports the and corporate strengths while encouraging new business development.   BioCrossroads provides money and support to life sciences businesses, launches new life sciences enterprises, expands collaboration and partnerships among Indiana’s life science institutions, expands science education and markets Indiana’s life sciences industry. The initiative has formed several new nonprofit organizations, including Indiana Health Information Exchange, BioCrossroadsLINX, OrthoWorx, Datalys Center and the Indiana Biosciences Research Institute.

INDIANAPOLIS (April 14, 2023) — BioCrossroads today released its annual analysis of capital invested to grow and support Indiana life sciences companies in 2022.

“We are pleased to report that Indiana experienced capital investment of more than $6.8 billion in 2022 that will directly result in the creation of 3,000 new life sciences sector jobs in the state,” said Jane Dunigan-Smith, BioCrossroads’ senior vice president, chief strategy officer and managing director of Seed Funds. “This includes more than $600 million in venture capital to support innovation and start-ups along with $2.8 billion in other capital investments for establishing, expanding, or upgrading Indiana life sciences facilities.”

Indiana’s life sciences sector contributed $77 billion to the state’s economy last year. Total market cap value grew by 20 percent over 2021, from $455.7 billion to $548.7 billion, driven largely by Eli Lilly and Company. Elevance Health, Corteva Agriscience, POINT Biopharma Global Inc., and Zimmer Biomet Holdings, Inc. also posted market cap gains.

Two companies, Orthopediatrics Corp. and POINT BioPharma, closed on public offerings with proceeds of $144 million and $125 million, respectively. Several notable mergers and acquisitions were completed, with five of them valued at more than $100 million, and Apria Healthcare was acquired by Owens & Minor for $1.6 billion.

“Indiana is fortunate to have a dynamic, healthy, and innovative life sciences community that includes our three research universities, industry anchors, and innovators in all corners of the state,” Dunigan-Smith said. “A uniquely collaborative community is also key to the impact this sector makes. Growing our significant impact will require a continuation of all our efforts and renewed focus in raising capital and further celebrating and supporting it.”

The report’s findings are based on information provided by the Indiana Economic Development Corporation (IEDC), investments tracked by BioCrossroads, the Small Business Innovation Research (SBIR)/Small Business Technology Transfer (STTR) program funding, Pitchbook Data, Inc., and other public sources. Highlights from the 2022 Life Sciences Capital Report showed:

See the full report here.

In 2021, BioCrossroads reported that more than $15 billion in capital was accessed by Indiana’s life sciences companies. More than $10 billion of that amount was due to the acquisition of Hill-Rom Holdings by Baxter International Inc. Highlights from the 2021 Life Sciences Capital Report showed:

About BioCrossroads

BioCrossroads is Indiana’s initiative to grow, advance and invest in the life sciences, a public-private collaboration that supports the region’s existing research and corporate strengths while encouraging new business development. BioCrossroads invests capital and provides support to life sciences businesses, launches new life sciences enterprises (Indiana Biosciences Research Institute, 16 Tech, Indiana Health Information Exchange, and OrthoWorx ), expands collaboration and partnerships among Indiana’s life science institutions, promotes science education and markets Indiana’s life sciences industry.

INDIANAPOLIS (March 21, 2023) — BioCrossroads announced today that Jane Dunigan-Smith and Mike Bolinder have joined the organization’s leadership team.

Dunigan-Smith, senior vice president, chief strategy officer and managing director of Seed Funds, comes to BioCrossroads after 19 years with Eli Lilly and Company where she spent a significant portion of her career in commercialization, corporate strategy and operations. She also has a strong background in accounting and finance, having spent the early part of her career as a Certified Public Accountant, and serves on the boards of Diagnotes, Inc. and Allinaire Therapeutics.

“Jane’s multi-faceted experience positions her to manage the Seed Funds and lead our strategy at a time when Indiana’s life sciences sector is expanding and innovating in multiple areas,” said Patty Martin, president and CEO, BioCrossroads. “One example is our work to establish Indiana as a global player in the field of radiopharmaceuticals. Her experience in pharmaceutical commercialization will be key as we develop strategic plans to support other promising sub-sectors while continuing to support our already established strengths in pharmaceuticals and biologics, medical devices and equipment, medical, research and testing laboratories and contract manufacturing organizations.”

Bolinder, senior vice president, external engagement, and chief innovation officer, has served in the life sciences sector for 20 years, most recently as CEO and executive director of Acacia Pharma Group plc, a publicly listed group of companies with headquarters in both Indianapolis, Ind., and Cambridge, UK. Prior to Acacia, he served as head of marketing and commercial strategy for the hospital division of Mallinckrodt Pharmaceuticals, following their acquisition of Cadence Pharmaceuticals. Previously, he worked at Eli Lilly and Company in various commercial roles of increasing responsibility.

“Mike has an ideal combination of experience working with large corporate and start-up entities to make an immediate impact through BioCrossroads,” said Martin. “There are so many opportunities ahead to continue to grow this sector, and he will be able to utilize his knowledge and experience to make some great things happen.”

About BioCrossroads

BioCrossroads is Indiana’s initiative to grow, advance and invest in the life sciences, a public-private collaboration that supports the region’s existing research and corporate strengths while encouraging new business development. BioCrossroads invests capital and provides support to life sciences businesses, launches new life sciences enterprises (Indiana Biosciences Research Institute, 16 Tech, Indiana Health Information Exchange, and OrthoWorx ), expands collaboration and partnerships among Indiana’s life science institutions, promotes science education and markets Indiana’s life sciences industry.

INDIANAPOLIS, (March 2, 2023) — Indiana leads the United States in pharmaceutical exports, according to new data from the Indiana Business Research Center at the Indiana University Kelley School of Business. Life sciences exports have always been a strong area for the state. Indiana has been one of the top three states in exports for all life sciences products – pharmaceuticals, medical device, and agbiosciences — for more than a decade. In 2022, $13 billion of these products were shipped all over the world.

In addition, 2022 saw a record amount of venture capital raised by Indiana start-ups for the third straight year – increasing to $620 million, an increase of nearly $200 million from 2021.

Other key indicators and statistics for 2022 include:

“Growth in key areas of Indiana’s life sciences industry, particularly in pharmaceutical manufacturing, where we now lead the U.S. in pharmaceutical exports, is strong. With 2022 announcements from Eli Lilly and Company and Evonik for major expansions, this trend will likely continue, which is great news for our economy and our workforce,” said Patty Martin, president and CEO of BioCrossroads. “It’s imperative that we continue working together to ensure that this critical sector is cultivated and promoted to drive more innovation and medical breakthroughs.”

Indiana is home to the global headquarters for: Cook Medical, Elanco Animal Health, Elevance Health, Eli Lilly and Company and Zimmer Biomet, and is the North American headquarters of Corteva Agriscience and Roche Diagnostics. Baxter, Beckman Coulter, Boston Scientific, Catalent, LabCorp, Mead Johnson/ Reckitt Benckiser, and Medtronic all host major operations in the state. In addition, the state has one of the largest and most prominent groups of contract development and manufacturing organizations in the U.S. with companies such as Azenta Life Sciences, Evonik, Inotiv, and Merck’s Contract Development and Manufacturing Organization.

About BioCrossroads

BioCrossroads (www.crossroadshealthventures.com) is Indiana’s initiative to grow the life sciences, a public-private collaboration that supports the region’s research and corporate strengths while encouraging new business development. BioCrossroads provides money and support to life sciences businesses, launches new life sciences enterprises, expands collaboration and partnerships among Indiana’s life science institutions, expands science education and markets Indiana’s life sciences industry. The initiative has formed several new nonprofit organizations, including Indiana Health Information Exchange, BioCrossroadsLINX, OrthoWorx, Datalys Center and the Indiana Biosciences Research Institute.

 

This data, generated by the Indiana Business Research Center at the Indiana University Kelley School of Business and BioCrossroads, are the most recent available.

Indianapolis, Nov. 14, 2022 – The State of Indiana, as well as seven Hoosier cities, have once again been recognized for their national life science strengths, according to Biotechnology Industry Organization (BIO) and TEConomy Partners’ biennial survey of the U.S. life sciences industry. The report, The U.S. Bioscience Industry: Fostering Innovation and Driving America’s Economy Forward, measures growth in the biosciences sector* from 2018 to 2021 for the entire country and each of the fifty states.

Indiana continued its top 10 employment ranking in the life sciences, with a sizeable workforce and industry concentration in the areas of agriculture feedstock and chemicals, drugs and pharmaceuticals, and medical devices and equipment. The state is also one of only eight states with employment specializations in three of five bioscience sectors. In addition, Indiana is ranked third for academic biosciences research and development (R&D) investment growth, increasing 23 percent from 2018 to 2021. Bloomington, Columbus, Evansville, Indianapolis, Lafayette, South Bend and Terre Haute are identified in the report as having significant life sciences activity. Bloomington and Lafayette were called out specifically for their diverse set of bioscience strengths – they are two of only nineteen cities in the U.S. to have employment specializations in three of the five industry subsectors.

“Indiana’s life sciences industry continues to drive innovation and rank in the top quintile nationwide,“ said Patty Martin, president and CEO of BioCrossroads. “Our employment numbers have increased by 8 percent over the last three years; our venture capital investments have grown; and we have maintained our status as a leader in the pharmaceutical, medical device and agriculture sectors.”

For large metropolitan statistical areas (MSAs) (employment greater than 250,000):

  • Indianapolis is 5th nationally for the number of Drugs and Pharmaceuticals jobs. It ranks 9th in the U.S. for Agricultural Feedstock and Chemicals jobs, and it is 25th for Bioscience-related distribution jobs.

For Medium MSAs (employment between 75,000 and 250,000):

  • Evansville ranks 11th for Agricultural Feedstock and Chemicals.
  • Lafayette has four subsectors with specialized employment concentration and has improved its standing significantly in two areas since the last report in 2020. It is now number 1 in Agricultural Feedstock and Chemicals and 6th nationally, moving up from 18th in 2020. In the Drugs and Pharmaceuticals category, Lafayette vaulted its position to 3rd from 13th.
  • South Bend-Mishawaka catapulted six positions from 2020 and is now 8th in Medical Devices.

For Small MSAs (employment less than 75,000):

  • Bloomington has been the number 1in the Medical Devices and Equipment category for specialized employment concentration for the last eight years. It is also the second highest region for Pharmaceuticals and is ranked 17th nationally for Medical Devices and Equipment, up from 20th in 2020. The region is also 13th in Bioscience-Related Distribution.
  • Columbus made its debut on the list of cities with high activity this year, ranking 15th for Pharmaceuticals.
  • Terre Haute moved up two places and is now 12th in the Drugs and Pharmaceuticals category.

“It’s impressive that seven Hoosier cities from North to South and East to West are being recognized for strong life sciences activity, spreading out the economic impact across the state,” said Kristen Jones, president of the Indiana Health Industry Forum. “It’s critical that we keep investing in this sector that provides jobs, tax revenue, and most importantly, life-saving products to Hoosiers.”

Indiana is home to the global headquarters of Elevance, Inc., Cook Medical, Corteva Agriscience, Eli Lilly and Company, and Zimmer Biomet and the North American headquarters of Roche Diagnostics. Beckman Coulter, Boston Scientific, Catalent Biologics, Covance, DePuy Orthopaedics, Express Scripts, Medtronic, and Reckitt Benckiser all host major operations in the state.

According to the report, 2.1 million people work in the U.S. bioscience industry, which has seen employment growth of 11 percent since 2018. In addition, the sector contributes more than $2.9 trillion to the U.S. economy.

The full report is available at www.bio.org

About BioCrossroads

BioCrossroads (www.crossroadshealthventures.com) is Indiana’s initiative to grow, advance and invest in the life sciences, supporting the region’s existing research and corporate strengths while encouraging new business development. BioCrossroads invests capital and provides support to life sciences businesses, launches new life sciences enterprises (Indiana Biosciences Research Institute, 16 Tech, Indiana Health Information Exchange, BioCrossroadsLINX, OrthoWorx and Datalys Center), expands collaboration and partnerships among Indiana’s life science institutions, promotes science education and markets Indiana’s life sciences industry.

About the Indiana Health Industry Forum (IHIF)

Established in 1994, the Indiana Health Industry Forum (IHIF) is a statewide trade association representing Indiana’s life sciences business community – manufacturers and service providers to the bio/pharma, medical device, and health IT sectors. It is our mission to secure Indiana’s position as a global leader in life sciences by advocating, connecting, promoting, and delivering tangible benefits on behalf of our diverse corporate members. To learn more, please visit us online at www.ihif.org.

*BIO/TEConomy defines the biosciences sector as Agricultural Feedstock and Chemicals, Drugs and Pharmaceuticals, Medical Devices and Research, Testing and Medical Laboratories and Bioscience-related Distribution

All cities listed are inclusive of their metropolitan statistical areas.